News from 2011
Richter Announces EMA Approval for PregLem's Esmya
Gedeon Richter Plc. announces that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion for Esmya® as pre-operative treatment of moderate to severe symptoms of uterine fibroids.
Tarsa Therapeutics Targets 2012 NDA Submission for its Ostora
Tarsa Therapeutics has confirmed that it is planning to submit a New Drug Application to the Food and Drug Administration in the second half of 2012 for OSTORA™, the company’s oral recombinant salmon calcitonin tablet for the treatment of postmenopausal osteoporosis.
Health Information Announces Investment from MVM Life Science Partners
Health Information, the dominant provider of point of dispensing messaging in the UK, announces that it has secured a first round of funding from MVM Life Sciences LLP.
Horizon Discovery Announces £11.3 Million Fundraising
Horizon Discovery, a leading provider of research tools to support the development of personalised medicines, has announced that it has completed a second closing of its Series C funding round, realising a cumulative total of £11.3m, with MVM Life Sciences LLP leading the second closing.
AccuVein Secures $22.5 million Series B Financing through MVM Life Science Partners and Bessemer Venture Partners
AccuVein Inc., a global leader in medical imaging technology and the creator of the AV300, the world’s first hand-held, non-contact vein illumination device, has announced that it has secured $22.5 million in a Series B financing.
Tarsa Therapeutics Advances its Oral Calcitonin for the Treatment and Prevention of Postmenopausal Osteoporosis
Tarsa Therapeutics has announced that the positive Phase III data from the registration trial of its oral calcitonin drug has been accepted for an oral presentation at the ASBMR Annual Meeting, patient enrolment is complete in the Phase II proof-of-concept prevention study in 120 postmenopausal women and Tarsa has closed an additional financing of $24.5 million.
Argenta Signs Integrated Services Agreement with Pulmagen Therapeutics
Galapagos NV (Euronext: GLPG) announced today that service division Argenta has signed a subcontracting agreement with Pulmagen Therapeutics Limited to perform integrated services on two respiratory projects.
AstraZeneca and Heptares Collaborate to Investigate Important GPCR Drug Targets
AstraZeneca and Heptares Therapeutics have announced that they have entered a four-year collaboration focused on the potential discovery and development of new medicines targeting G-protein coupled receptors.
Heptares Grants Shire an Exclusive Option to License Novel Adenosine A2a Antagonist
Heptares Therapeutics has announced that it has signed an exclusive option agreement with Shire Pharmaceuticals for a novel adenosine A2a antagonist discovered by Heptares and currently in preclinical development.
Lombard Medical Announces £27.5 million Financing
Lombard Medical Technologies PLC (AIM: LMT), the specialist medical devices company, has announced a £27.5 million financing, with Abingworth LLP and MVM Life Science Partners LLP who have committed to invest, in aggregate, up to £13.0 million.
Heptares and Takeda Initiate Drug Discovery Collaboration
Heptares and Takeda initiate drug discovery collaboration focused on GPCR linked to CNS disorders. The deal includes £4.5 million upfront cash and equity, up to £60.5 million in future milestone payments, and royalties on product sales.
Tarsa Therapeutics, Inc. Announces Positive Phase III Data
Tarsa Therapeutics has announced that the Phase III trial of its oral calcitonin in the treatment of postmenopausal osteoporosis was successfully concluded and yielded positive top-line results.
Amgen Completes Acquisition of BioVex
Amgen have announced the completion of the acquisition of BioVex Group, Inc., for up to $1 billion. The transaction provides Amgen with BioVex’s lead product candidate, OncoVEXGM-CSF, a novel oncolytic vaccine in Phase 3 clinical development.
Meda Acquires Antula
Meda has signed an agreement to acquire Antula with well-known brands such as SB12, Anti, Zyx, Becur, Ac3, Lactal Balans, Eeze, Nalox and Inside for SEK 1,800 million on a debt-free basis.
BioVex to be acquired by Amgen for up to $1bn
Amgen (Nasdaq: AMGN) and Biovex Group, Inc. announce that the companies have entered into a definitive acquisition agreement under which Amgen has agreed to acquire BioVex Group, Inc. for up to $1 billion.